ETF Daily News15h
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Stake Increased by Algert Global LLC
Algert Global LLC increased its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 401.3% ...
Zacks.com on MSN1d
FDA Begins Review of Alnylam's sNDA for Expanded Amvuttra Use
Alnylam Pharmaceuticals ALNY announced that the FDA has accepted its supplemental new drug application (sNDA) seeking the ...
Alnylam Pharma’s Regulatory Challenges and Market Uncertainty Lead to Hold Rating
Leerink Partners analyst Mani Foroohar has maintained their neutral stance on ALNY stock, giving a Hold rating on November 25.Don't Miss our ...
Alnylam Pharmaceuticals: Strategic Positioning and Growth Opportunities Reinforce Buy Rating Amidst Competitive ATTR-CM Market
Canaccord Genuity analyst Whitney Ijem maintained a Buy rating on Alnylam Pharma (ALNY – Research Report) yesterday and set a price target of ...
Yahoo Finance3h
Alnylam to Webcast Presentation at Piper Sandler 36th Annual Healthcare Conference
CAMBRIDGE, Mass., November 27, 2024--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company ...
BioSpace2d
Days After BridgeBio Approval, FDA Agrees to Review Alnylam’s Amvuttra in ATTR-CM
The FDA has accepted Alnylam’s supplemental New Drug Application for Amvuttra on the heels of BridgeBio’s Attruby nod, ...
Charles Schwab Investment Management Inc. Buys 16,756 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Charles Schwab Investment Management Inc. increased its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – ...
Yahoo9d
Alnylam reveals trial outcomes of nucresiran for ATTR amyloidosis treatment
Alnylam Pharmaceuticals has revealed new interim data from its Phase I trial of nucresiran, a ribonucleic acid interference ...
Hemophilia B Treatment Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Medication, Pipeline, Epidemiology and Companies by DelveInsight
DelveInsight’s “Hemophilia B Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding ...
KalVista Pharmaceuticals Appoints Laurence Reid, Ph.D., to Board of Directors
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that Laurence Reid, Ph.D., has been appointed to the Company’s ...
Reuters4d
US FDA approves BridgeBio's drug for rare heart condition (Nov 22)
Tafamidis and acoramidis are designed to stabilize the faulty proteins, unlike a drug by Alnylam Pharmaceuticals that which works by reducing the production of the protein. Alnylam's vutrisiran is ...